From-Steubing, McGuiness & Manaras LLP

CHANGE OF

CORRESPONDENCE ADDRESS

978 264 9119

T-330 P.004/015 F-688

PTO/SB/122 (10-01) Approved for use through 10/31/2002. OMB 0551-0035 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMG control number. 307452 **Application Number**

Filling Date

First Named Inventor

Applic	auon					Poortage			
Address to:		Art Unit				2131			
Assistant Commissioner for Patents		Examiner Name				Jackson			
Washington, D.C. 20231			Attorney Docket Number			120-300			
Please change the Correspondence Address for the above-identified application to: X Customer Number Type Customer Number Here OR									
Firm or Individual Name Steubing McGuinness & Manaras LLP						_			
Address 125 Nagog Park									
Address									
City	Acton		State	Acton		ZIP	01720		
Country	Country USA								
Telephone	978-264-6664		Fax	978-264-911		ıg · · · ·			
This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124). I am the: Applicant/Inventor. Assignee of record of the entire interest. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). X Attorney or Agent of record. Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number									
	7, 000 3								
NOTE: Signatures of all the inv	nations or acclusions of month of H	ha antira i		- 44 -:-					
torms if more than one signature	e is required, see below.	iic elime i	Interest C	i nien	representative(s) are n	equired. Submit n	nulapie	

Burden Hour Statement. This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.